MCID: CLC006
MIFTS: 47

Calcinosis

Categories: Metabolic diseases

Aliases & Classifications for Calcinosis

MalaCards integrated aliases for Calcinosis:

Name: Calcinosis 12 29 54 44 15 70
Pathologically Calcified Structure 12
Pathologic Calcification 12

Classifications:



External Ids:

Disease Ontology 12 DOID:182
MeSH 44 D002114
NCIt 50 C3672
SNOMED-CT 67 237881004
UMLS 70 C0006663

Summaries for Calcinosis

Disease Ontology : 12 A calcium metabolism disease that is the result of the formation of calcium deposits in any soft tissue.

MalaCards based summary : Calcinosis, also known as pathologically calcified structure, is related to tumoral calcinosis, normophosphatemic, familial and tumoral calcinosis, hyperphosphatemic, familial, 1. An important gene associated with Calcinosis is SAMD9 (Sterile Alpha Motif Domain Containing 9), and among its related pathways/superpathways are Endochondral Ossification and Lung fibrosis. The drugs Sevelamer and Calcium acetate have been mentioned in the context of this disorder. Affiliated tissues include bone, skin and kidney, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Calcinosis is the formation of calcium deposits in any soft tissue. It is a rare condition that has many... more...

Related Diseases for Calcinosis

Diseases related to Calcinosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 579)
# Related Disease Score Top Affiliating Genes
1 tumoral calcinosis, normophosphatemic, familial 33.1 SAMD9L SAMD9 ENPP1
2 tumoral calcinosis, hyperphosphatemic, familial, 1 32.9 SAMD9 PHEX MEPE KL GALNT3 FGF23
3 familial tumoral calcinosis 32.4 TNF SAMD9L SAMD9 PHEX KL GALNT3
4 hyperparathyroidism 31.3 PHEX KL FGF23 CALCA
5 hyperphosphatemia 31.2 SPP1 PHEX MGP KL GALNT3 FGF23
6 calciphylaxis 31.1 MGP FGF23 AHSG
7 secondary hyperparathyroidism 31.1 PHEX KL FGF23 CALCA
8 end stage renal disease 30.8 TNF SPP1 MGP KL FGF23
9 scleroderma, familial progressive 30.7 FBN1 CENPB
10 kidney disease 30.6 TNF SPP1 MGP FGF23 ENPP1 AHSG
11 adult dermatomyositis 30.6 TNF GPT
12 hypervitaminosis d 30.6 KL GALNT3 FGF23 CALCA
13 primary hyperparathyroidism 30.6 KL FGF23 CALCA AHSG
14 angioid streaks 30.4 MGP GALNT3 ENPP1 AHSG
15 hyperostosis 30.4 SPP1 KL GALNT3 FGF23 ANKH
16 rickets 30.4 PHEX MEPE KL FGF23 ENPP1
17 uremia 30.3 TNF SPP1 MGP ENPP1 AHSG
18 bone resorption disease 30.3 TNF SPP1 FGF23 CALCA
19 renal osteodystrophy 30.3 MGP FGF23 CALCA
20 skin atrophy 30.3 LMNA KL FGF23
21 dental pulp calcification 30.3 SAMD9 GALNT3
22 hypophosphatemic rickets, x-linked recessive 30.3 PHEX MEPE FGF23 ENPP1
23 pulmonary alveolar microlithiasis 30.2 MEPE GALNT3 FGF23
24 tympanosclerosis 30.0 TNF SPP1 CALCA
25 periarthritis 30.0 ENPP1 ANKH
26 arteriosclerosis 30.0 SPP1 MGP KL GPT FBN1
27 chronic kidney disease 30.0 TNF SPP1 MGP KL FGF23 ENPP1
28 paget's disease of bone 29.9 TNF SPARC CALCA
29 oncogenic osteomalacia 29.9 PHEX MEPE FGF23
30 hypophosphatemic rickets, autosomal dominant 29.8 PHEX MEPE KL GALNT3 FGF23 ENPP1
31 ankylosis 29.8 TNF ENPP1 ANKH
32 hypophosphatemia 29.8 SPP1 PHEX MEPE KL FGF23 ENPP1
33 sclerosing cholangitis 29.7 TNF HLA-DRB1 GPT
34 cholangitis 29.7 TNF HLA-DRB1 GPT
35 autoimmune hepatitis 29.7 TNF HLA-DRB1 GPT
36 nevus, epidermal 29.7 PHEX MEPE GALNT3 FGF23 ENPP1
37 polycystic kidney disease 29.6 TNF KL FGF23 ENPP1 AHSG
38 connective tissue disease 29.6 TNF SPP1 HLA-DRB1 FBN1 CENPB CALCA
39 pseudoxanthoma elasticum 29.6 SPP1 SPARC MGP FBN1 ENPP1 ANKH
40 osteomalacia 29.6 PHEX MEPE FGF23 ENPP1 CALCA
41 bone disease 29.5 TNF SPP1 SPARC PHEX FGF23 CALCA
42 aortic valve disease 2 29.5 SPP1 SPARC MGP FBN1
43 abdominal tuberculosis 29.5 TNF GPT
44 hypophosphatasia 29.4 SPP1 PHEX FGF23 ENPP1 ANKH
45 mccune-albright syndrome 29.4 SPARC FGF23 FBN1
46 enthesopathy 29.3 TNF PHEX MEPE KL GALNT3 FGF23
47 varicose veins 29.3 TNF MGP FBN1
48 osteoporosis 29.3 TNF SPP1 SPARC MGP MEPE LMNA
49 inguinal hernia 29.2 HLA-DRB1 FBN1 CALCA
50 mineral metabolism disease 28.9 SPP1 PHEX MGP MEPE KL GALNT3

Graphical network of the top 20 diseases related to Calcinosis:



Diseases related to Calcinosis

Symptoms & Phenotypes for Calcinosis

GenomeRNAi Phenotypes related to Calcinosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.58 LMNA
2 Decreased viability GR00249-S 9.58 ANKH ENPP1 LMNA SPP1
3 Decreased viability GR00381-A-1 9.58 CALCA MGP
4 Decreased viability GR00381-A-2 9.58 MGP
5 Decreased viability GR00381-A-3 9.58 MGP
6 Decreased viability GR00386-A-1 9.58 ANKH HLA-DRB1 KL LMNA SAMD9
7 Decreased viability GR00402-S-2 9.58 ENPP1 FBN1 GPT TNF

MGI Mouse Phenotypes related to Calcinosis:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.34 AHSG ANKH CENPB ENPP1 FBN1 FGF23
2 cardiovascular system MP:0005385 10.28 ANKH ENPP1 FBN1 FGF23 GALNT3 KL
3 homeostasis/metabolism MP:0005376 10.28 AHSG ANKH ENPP1 FBN1 FGF23 GALNT3
4 cellular MP:0005384 10.26 ANKH CENPB ENPP1 FBN1 GALNT3 KL
5 hematopoietic system MP:0005397 10.23 ANKH FBN1 FGF23 GALNT3 KL LMNA
6 immune system MP:0005387 10.22 ANKH ENPP1 FBN1 FGF23 GALNT3 KL
7 craniofacial MP:0005382 10.21 ANKH ENPP1 FBN1 GALNT3 KL LMNA
8 integument MP:0010771 10.07 ENPP1 FBN1 FGF23 GALNT3 KL LMNA
9 limbs/digits/tail MP:0005371 10.06 AHSG ANKH ENPP1 FBN1 FGF23 GALNT3
10 muscle MP:0005369 9.96 AHSG ANKH ENPP1 FBN1 GALNT3 KL
11 hearing/vestibular/ear MP:0005377 9.95 AHSG ANKH ENPP1 KL LMNA PHEX
12 renal/urinary system MP:0005367 9.81 ENPP1 FBN1 FGF23 GALNT3 KL LMNA
13 respiratory system MP:0005388 9.56 ANKH FBN1 FGF23 KL LMNA MGP
14 skeleton MP:0005390 9.5 AHSG ANKH ENPP1 FBN1 FGF23 GALNT3

Drugs & Therapeutics for Calcinosis

Drugs for Calcinosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevelamer Approved Phase 4 52757-95-6
2
Calcium acetate Approved, Investigational Phase 4 62-54-4
3
Atorvastatin Approved Phase 4 134523-00-5 60823
4
Vitamin K1 Approved, Investigational Phase 4 84-80-0 5284607
5
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
6
Rivaroxaban Approved Phase 4 366789-02-8
7
Warfarin Approved Phase 4 81-81-2 6691 54678486
8
fluindione Approved, Investigational Phase 4 957-56-2
9
Phenprocoumon Approved, Investigational Phase 4 435-97-2 9908 54680692
10
Ethanol Approved Phase 4 64-17-5 702
11
Apixaban Approved Phase 4 503612-47-3 10182969
12
Cinacalcet Approved Phase 4 226256-56-0 156419
13
Phenindione Approved, Investigational Phase 4 83-12-5 4760
14
Dalteparin Approved Phase 4 9005-49-6
15
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
16
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
17 Menaquinone Investigational Phase 4 1182-68-9
18
Coumarin Experimental Phase 4 91-64-5 323
19 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
20 Liver Extracts Phase 4
21 Vitamin K Phase 4
22 Antifibrinolytic Agents Phase 4
23 Coagulants Phase 4
24 naphthoquinone Phase 4
25 Hemostatics Phase 4
26 Vitamin K 2 Phase 4
27 Serine Proteinase Inhibitors Phase 4
28 Antithrombins Phase 4
29 Factor Xa Inhibitors Phase 4
30 Antithrombin III Phase 4
31 HIV Protease Inhibitors Phase 4
32 Anticoagulants Phase 4
33
protease inhibitors Phase 4
34 Butylated Hydroxytoluene Phase 4
35 Hormone Antagonists Phase 4
36 Heparin, Low-Molecular-Weight Phase 4
37 Antivitamins K Phase 4
38 Antidotes Phase 4
39 Antioxidants Phase 4
40 Protective Agents Phase 4
41 Chelating Agents Phase 4
42 sodium thiosulfate Phase 4
43 Anti-Infective Agents Phase 4
44 Anti-Bacterial Agents Phase 4
45 Antitubercular Agents Phase 4
46 Pharmaceutical Solutions Phase 4
47
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
48
Inositol Approved, Investigational, Withdrawn Phase 2, Phase 3 87-89-8
49
Magnesium hydroxide Approved, Investigational Phase 2, Phase 3 1309-42-8
50
Spironolactone Approved Phase 3 1952-01-7, 52-01-7 5833

Interventional clinical trials:

(show top 50) (show all 138)
# Name Status NCT ID Phase Drugs
1 Influence of Vitamin K2 Administration on Vessel Calcification Markers in Patients With Chronic Kidney Disease Unknown status NCT01101698 Phase 4 Vitamin K2+10μg cholecalciferol;Vitamin D
2 Regulation of Bone Mineralization in Renal Osteodystrophy Unknown status NCT01799317 Phase 4 Vitamin D2
3 Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
4 CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2) Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
5 The Effect of Replacement of Vitamin K Antagonist by Rivaroxaban With or Without Vitamin K2 Supplementation on Vascular Calcifications in Chronic Hemodialysis Patients: A Randomized Controlled Trial Completed NCT02610933 Phase 4 rivaroxaban
6 Risk Factors for Vascular Calcifications in Hemodialysis Patients: to What Extent is Vitamin K2 Deficiency Involved? Completed NCT02876354 Phase 4 Menaquinone
7 A Phase IV, Randomized, Single-center Study of the Effects of Calcitriol and Paricalcitol on Vascular Calcification in Chronic Kidney Disease Stages 3 and 4 Completed NCT00752102 Phase 4 Calcitriol (Rocaltrol®);Paricalcitol
8 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque Completed NCT02090075 Phase 4 apixaban;warfarin
9 Influence of Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification in Patients With Atrial Fibrillation and/ or Pulmonary Embolism (IRIVASC- Trial) Completed NCT02066662 Phase 4 Rivaroxaban or Marcumar
10 Randomised Controlled Trial of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease: A Pilot Study Completed NCT00395382 Phase 4 Alendronate;Placebo
11 Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients? Completed NCT00261625 Phase 4 alendronate
12 A Randomized Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease (CKD) Receiving Hemodialysis Completed NCT00379899 Phase 4 cinacalcet
13 The VICTORIA Study (Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation) Comparison Anti-vitamin K Versus Anti-Xa. Completed NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
14 Effect of Vitamin K2 Supplementation on Vascular Calcification in Hemodialysis Patients: a Controlled Randomized Trial. Completed NCT04539418 Phase 4 Vitamin K 2
15 Effects of Melatonin on Progression of Coronary Artery Calcification Recruiting NCT03966235 Phase 4 Melatonin 3 mg;Placebo
16 A Comparative Study of the Efficacy of Intralesional Sodium Thiosulfate Versus Intralesional Normal Saline for the Treatment of Dystrophic and Idiopathic Calcinosis Cutis, A Double-Blind Randomized Placebo-Controlled Trial Terminated NCT03639779 Phase 4 Sodium Thiosulfate
17 A Prospective, Randomized, Open-Label Trial Investigating the Effect of 1 Alpha Hydroxy Vitamin D2 on the Development of Coronary Calcification in New ESRD Patients Using the 1-84/7-84 PTH Ratio to Determine Dosing Withdrawn NCT00502268 Phase 4 Doxercalciferol administration;Doxercalciferol administered by 1-84-7-84
18 Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications Unknown status NCT01000233 Phase 2, Phase 3
19 The Effect of Oral Magnesium Supplementation on Vascular Calcification in Chronic Kidney Disease - A Randomized Clinical Trial Unknown status NCT02542319 Phase 2, Phase 3
20 Calcinosis Cutis: Therapeutic Effects of Extracorporeal Shock Wave Therapy (ESWT) Completed NCT01683500 Phase 3
21 The Use of Bisphosphonates to Prevent or Delay the Progression of Vascular Calcification in End-Stage Renal Disease: A Randomized Controlled Trial Completed NCT00687661 Phase 3 Bisphosphonate;Placebo
22 Food Supplementation With Vitamin K2 to Activate MGP as an Endogenous Inhibitor of Vascular Calcification in Hemodialysis Patients Completed NCT01407601 Phase 3
23 Vitamin K Containing Nutritional Supplement for Activation of Matrix-GIa-proteins (MGP) and Inhibition of Aortic Valve Calcification Process Completed NCT00785109 Phase 3
24 Randomized Prospective Open Interventional Multi-centre Study on Finding the Optimal Dose of Vitamin K2 Supplements for Hemodialysis Patients Completed NCT01675206 Phase 3
25 Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease: Prospective, Randomized, Controlled Study Completed NCT00481364 Phase 3 atorvastatin;placebo
26 Effect of Spironolactone on the Progression of Coronary Calcification in Peritoneal Dialysis Patients Completed NCT03314493 Phase 3 Spironolactone 25Mg Tablet
27 Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification Completed NCT00183001 Phase 3 Vitamin K
28 Effect of Evolocumab on Coronary Artery Plaque Volume and Composition by Coronary CTA (CCTA) and Microcalcification by F18-NaF PET: A Phase 3 Study Recruiting NCT03689946 Phase 3 Evolocumab
29 The Safety and Effectiveness of the SAPIEN 3 and SAPIEN 3 Ultra Valve in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification Who Are Not Candidates for Standard Mitral Valve Surgery. Recruiting NCT04408430 Phase 2, Phase 3
30 Impact of Metformin on Peripheral Arterial Calcification in Type 1 Diabetes: a Double Blind Randomized Controlled Trial Not yet recruiting NCT04583462 Phase 3 Metformin;Placebo
31 Randomized Control Trial of Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease Unknown status NCT01364688 Phase 2 oral alfacalcidol;no drug
32 Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis Completed NCT01572844 Phase 2 Sodium thiosulfate
33 Phase II Study of Calcitonin for Tumoral Calcinosis Completed NCT00004358 Phase 2 calcitonin
34 A Pilot Study to Evaluate the Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis Completed NCT02663895 Phase 2 Oral treprostinil
35 The Treatment Effect of Intravenous Sodium Thiosulfate on Coronary Calcification in Patients on Hemodialysis Completed NCT00720772 Phase 2 25% intravenous (IV) sodium thiosulfate
36 A Phase II Randomized, Placebo-Controlled, Double-Blinded Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification in Patients With Moderate Calcific Aortic Valve Stenosis Completed NCT02481258 Phase 2 Ataciguat (HMR1766)
37 The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects With End-Stage Renal Disease Treated With Haemodialysis - A Randomised Clinical Trial Completed NCT02977117 Phase 2
38 SALTIRE II: Bisphosphonates and RANKL Inhibition in Aortic Stenosis Completed NCT02132026 Phase 2 Denosumab;Alendronic Acid;Denosumab Placebo;Alendronic Acid Placebo
39 A Double-blind, Randomised, Placebo-controlled Study to Assess the Effect of SNF472 on Progression of Cardiovascular Calcification on Top of Standard of Care in End-stage-renal-disease (ESRD) Patients on Hemodialysis (HD) Completed NCT02966028 Phase 2 SNF472;Placebo
40 An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
41 Surgical Implantation of TRAnscatheter vaLve in Native Mitral Annular Calcification (SITRAL) Study Recruiting NCT02830204 Phase 2
42 Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study Recruiting NCT03582800 Phase 2 STS
43 The Effect of Etelcalcetide on Bone-tissue Properties and Calcification Propensity in End Stage Kidney Disease Recruiting NCT03960437 Phase 2 Etelcalcetide
44 An Open-label, Non-Randomized, Single-Arm Pilot Study to Evaluate the Effectiveness of Etidronate Treatment for Arterial Calcifications Due to Deficiency in CD73 (ACDC) Active, not recruiting NCT01585402 Phase 2 Etidronate
45 Treatment to Reduce Vascular Calcification in Hemodialysis Patients Using Vitamin K (Trevasc-HDK): A Study Protocol for a Randomized Controlled Trial Active, not recruiting NCT02870829 Phase 2 menaquinone-7
46 Inhibit Progression of Coronary Artery Calcification With Vitamin K in HemoDialysis Patients: The iPACK-HD Study Active, not recruiting NCT01528800 Phase 2 Vitamin K1;Microcrystalline Methylcellulose
47 A Comparative Trial of Calcitriol Versus Placebo for the Preservation of Bone Mass and Strength After Kidney Transplantation Active, not recruiting NCT02224144 Phase 2 Vitamin D3;Calcitriol;Placebo
48 The Effect of Sodium Bicarbonate (Nephrotrans®) on Calcification Propensity of Serum in Kidney Transplant Recipients Not yet recruiting NCT03301558 Phase 2 Low dose sodium bicarbonate;High dose sodium bicarbonate
49 A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis (STS-CALC) Withdrawn NCT01918904 Phase 2 Sodium thiosulfate;Placebo
50 Arterial Imaging of Inflammation and Resolution After Endovascular Surgery Completed NCT03590769 Phase 1 18F-FDG

Search NIH Clinical Center for Calcinosis

Cochrane evidence based reviews: calcinosis

Genetic Tests for Calcinosis

Genetic tests related to Calcinosis:

# Genetic test Affiliating Genes
1 Calcinosis 29

Anatomical Context for Calcinosis

MalaCards organs/tissues related to Calcinosis:

40
Bone, Skin, Kidney, Heart, Breast, Lung, Brain

Publications for Calcinosis

Articles related to Calcinosis:

(show top 50) (show all 3939)
# Title Authors PMID Year
1
Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis. 54 61
18448482 2008
2
Expression of osteonectin and matrix Gla protein in scleroderma patients with and without calcinosis. 54 61
17050587 2006
3
Cutaneous calcification in patients with end-stage renal disease: a regulated process associated with in situ osteopontin expression. 61 54
16847207 2006
4
A homozygous mutation in the lamin A/C gene associated with a novel syndrome of arthropathy, tendinous calcinosis, and progeroid features. 54 61
16278265 2006
5
Fine specificity of anti-fibrillin-1 autoantibodies in primary pulmonary hypertension syndrome. 61 54
10849372 2000
6
Kinetics of anti-fibrillin-1 autoantibodies in MCTD and CREST syndrome. 54 61
10756089 2000
7
[Diabetic macroangiopathy in humans]. 54 61
9501570 1997
8
von Willebrand factor in juvenile dermatomyositis. 61 54
7738956 1995
9
Anticentromere autoantibodies. Evaluation of an ELISA using recombinant fusion protein CENP-B as antigen. 61 54
8129780 1994
10
Echocardiographic study of juvenile dermatomyositis patients: new insights from speckle-tracking-derived strain. 61
32989504 2021
11
Calcinosis Cutis as the Initial Manifestation of Limited Scleroderma. 61
31985726 2021
12
Tumoral calcinosis. 61
33795242 2021
13
Juvenile dermatomyositis: a case of delayed recognition with unusual complication of nephrocalcinosis. 61
33795282 2021
14
Radiation-induced morphea and dystrophic calcinosis cutis of the breast. 61
33650142 2021
15
Ultrasound guided aspiration of massive periarticular calcinosis in patient with scleroderma. 61
33773446 2021
16
Conjunctival calcinosis circumscripta in a dog: Treatment combining surgical resection and amniotic membrane grafting. 61
33544454 2021
17
Scalp calcinosis in juvenile dermatomyositis. 61
33677594 2021
18
Analysis of the first 5 years of an interdisciplinary Rheumatology-Dermatology clinic. 61
32687656 2021
19
Autoantibody Profile of Children with Juvenile Dermatomyositis. 61
33694062 2021
20
Surgical Debulking for Symptomatic Management of Calcinosis Cutis of the Hand and Upper Extremity in Systemic Sclerosis. 61
33795151 2021
21
Calcinosis in systemic sclerosis. 61
33812021 2021
22
A narrative review of imaging in calcinosis associated with systemic sclerosis. 61
33755836 2021
23
Calcinosis cutis in limited cutaneous systemic sclerosis. 61
33711165 2021
24
Does hand involvement in systemic sclerosis limit completion of patient-reported outcome measures? 61
33094395 2021
25
The prevalence and significance of anti-PM/Scl antibodies in systemic sclerosis. 61
33775087 2021
26
Tumoral calcinosis due to severe hyperphosphatemia and secondary hyperparathyroidism without vascular calcification in a hemodialysis patient. 61
33433319 2021
27
The Successful Treatment of Deep Soft-tissue Calcifications with Topical Sodium Thiosulphate and Acetazolamide in a Boy with Hyperphosphatemic Familial Tumoral Calcinosis due to a Novel Mutation in FGF23 61
33685073 2021
28
Differential diagnosis of T2 hypointense masses in musculoskeletal MRI. 61
33651128 2021
29
Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. 61
32681367 2021
30
Itchy plaques on trunk and feet in a patient with dark skin: a case of Dystrophic Calcinosis Cutis superimposed on Lichen Simplex Chronicus. 61
32805751 2021
31
Presentation of calcinosis cutis 35 years after silicone nasal implant reconstruction. 61
33526537 2021
32
Scleroderma-associated cutaneous calcinosis: a remarkable regression post stem cell transplantation. 61
32845441 2021
33
Idiopathic calcinosis in a paediatric patient. 61
31488401 2021
34
Idiopathic Tumoral Calcinosis. 61
33615135 2021
35
Use of calcium channel blockers in dermatology: a narrative review. 61
33612036 2021
36
A novel homozygous variant in exon 10 of the GALNT3 gene causing hyperphosphatemic familial tumoral calcinosis in a family from North India. 61
33614378 2021
37
Resolution of calcinosis using bisphosphonates in overlap syndrome - a case report. 61
33632332 2021
38
Treatment of Calcinosis in Juvenile Dermatomyositis. 61
33555459 2021
39
Systemic sclerosis skin is a 'primed' microenvironment for soft tissue calcification - a hypothesis. 61
33585894 2021
40
High proton pump inhibitor exposure increases risk of calcinosis in systemic sclerosis. 61
32829395 2021
41
Prevalence and clinical association with calcinosis cutis in early systemic sclerosis. 61
33566708 2021
42
The clinical phenotype of Systemic Sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. 61
33580257 2021
43
Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis. 61
33360233 2021
44
Arthroscopy in rheumatology: where have we been? Where might we go? 61
33257961 2021
45
Review of 189 Consecutive Female Genital Skin and Mucosal Biopsies Submitted to an Academic Dermatopathology Practice. 61
32915210 2021
46
Neuropathologic Findings in Chronic Kidney Disease (CKD). 61
33579545 2021
47
Basal Cell Carcinoma With Calcification: Case Report of Calcifying Basal Cell Carcinoma and Review of Calcinosis Cutis Associated With Basal Cell Carcinoma. 61
33614324 2021
48
Intravenous sodium thiosulfate combined with parathyroidectomy as a cure for uremic tumoral calcinosis in a hemodialysis patient. 61
32622037 2021
49
Calcinosis cutis and severe hypercalcemia in a patient on long-term hemodialysis. 61
33063434 2021
50
Beneficial Response to Phosphate Lowering Therapy in Normophosphatemic Tumoral Calcinosis. 61
33452789 2021

Variations for Calcinosis

Expression for Calcinosis

Search GEO for disease gene expression data for Calcinosis.

Pathways for Calcinosis

Pathways related to Calcinosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.14 SPP1 MGP ENPP1
2 10.93 TNF SPP1 CALCA
3 10.56 TNF SPP1 MEPE FGF23 FBN1
4 10.45 TNF SPP1 CALCA

GO Terms for Calcinosis

Cellular components related to Calcinosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 TNF SPP1 SPARC MGP MEPE KL
2 extracellular matrix GO:0031012 9.56 MGP MEPE FBN1 AHSG
3 endoplasmic reticulum lumen GO:0005788 9.55 SPP1 MEPE FGF23 FBN1 AHSG
4 extracellular space GO:0005615 9.36 TNF SPP1 SPARC KL HLA-DRB1 GPT

Biological processes related to Calcinosis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.89 SPP1 MEPE FGF23 FBN1 AHSG
2 extracellular matrix organization GO:0030198 9.85 TNF SPP1 SPARC FBN1
3 fibroblast growth factor receptor signaling pathway GO:0008543 9.71 KL GALNT3 FGF23
4 ossification GO:0001503 9.67 SPP1 SPARC MGP AHSG
5 skeletal system development GO:0001501 9.65 PHEX MEPE FBN1 ANKH AHSG
6 negative regulation of glucose import GO:0046325 9.57 TNF ENPP1
7 cellular response to vitamin D GO:0071305 9.56 PHEX FGF23
8 cellular response to parathyroid hormone stimulus GO:0071374 9.52 PHEX FGF23
9 cellular phosphate ion homeostasis GO:0030643 9.51 FGF23 ENPP1
10 negative regulation of bone mineralization GO:0030502 9.5 FGF23 ENPP1 AHSG
11 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.48 KL FGF23
12 sequestering of triglyceride GO:0030730 9.46 TNF ENPP1
13 biomineral tissue development GO:0031214 9.46 SPP1 PHEX MEPE ENPP1
14 inorganic diphosphate transport GO:0030505 9.43 ENPP1 ANKH
15 cellular protein metabolic process GO:0044267 9.43 SPP1 MEPE FGF23 FBN1 CALCA AHSG
16 response to sodium phosphate GO:1904383 9.4 PHEX FGF23
17 regulation of bone mineralization GO:0030500 9.02 MGP FGF23 ENPP1 ANKH AHSG

Molecular functions related to Calcinosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 polysaccharide binding GO:0030247 8.96 HLA-DRB1 ENPP1
2 extracellular matrix structural constituent GO:0005201 8.92 SPARC MGP MEPE FBN1

Sources for Calcinosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....